Loading people...
Amy Schulman primarily invests in companies within the life sciences and healthcare industries. Her focus areas include biotechnology, pharmaceuticals, medical devices, and innovative digital health solutions.
Amy Schulman works as a Managing Partner at Polaris Partners. Polaris Partners is a venture capital firm with offices in Boston and San Francisco.
Amy Schulman is a Managing Partner at Polaris Partners and the Polaris Innovation Fund, operating out of Boston and New York. Prior to transitioning to venture capital in 2014, she served as Executive Vice President, General Counsel, and Business Unit President at Pfizer, where she successfully led the $11.85 billion sale of the Pfizer Nutrition division to Nestlé. She also co-founded and served as the first CEO of Lyndra Therapeutics, and she currently holds a position as a Senior Lecturer at Harvard Business School. Schulman maintains extensive corporate governance responsibilities, serving as Chair of Alnylam Pharmaceuticals and holding board seats at Elevance Health and the Mount Sinai Health System. Equipped with a JD from Yale Law School and a BA from Wesleyan University, Schulman currently focuses on incubating early-stage biotechnology startups and directing life sciences investments.
Amy Schulman stands as a distinguished Managing Partner at Polaris Partners, a leading venture capital firm renowned for its investments in technology and healthcare. At Polaris, Ms. Schulman plays a pivotal role in identifying, nurturing, and scaling innovative companies within the dynamic life sciences and healthcare sectors. Her strategic acumen and deep industry knowledge are instrumental in guiding portfolio companies from their foundational stages to significant market success.
Her investment philosophy is deeply rooted in fostering groundbreaking advancements in healthcare. Ms. Schulman's portfolio interests span a wide array of areas, including biotechnology, pharmaceuticals, medical devices, and digital health solutions. She is particularly adept at recognizing opportunities where scientific innovation meets unmet medical needs, driving the development of therapies and technologies that have the potential to transform patient care globally. Her leadership helps Polaris Partners maintain its position at the forefront of healthcare venture capital.
Before her tenure at Polaris Partners, Ms. Schulman built an impressive career marked by diverse leadership roles across legal, operational, and executive functions. She served as Executive Vice President and General Counsel at Pfizer, Inc., a global pharmaceutical giant. In this critical role, she was a key member of the Executive Leadership Team, overseeing complex legal matters and contributing to strategic corporate decisions. Her responsibilities at Pfizer extended beyond legal affairs, as she also held the position of President of Pfizer Nutrition and led Pfizer's consumer healthcare business. These operational roles provided her with invaluable experience in commercial strategy, product development, and global market expansion.
Prior to her impactful time at Pfizer, Ms. Schulman was a respected partner at the prestigious law firm Ropes & Gray. There, she specialized in intellectual property and product liability litigation, honing her analytical skills and understanding of the regulatory and legal landscapes critical to the life sciences industry. This extensive background, encompassing high-stakes legal practice, executive operational leadership, and strategic corporate governance, provides her with a unique and comprehensive perspective on the challenges and opportunities within the healthcare ecosystem.
This rich tapestry of experience makes Amy Schulman an exceptionally effective investor and mentor. Her ability to navigate complex regulatory environments, understand scientific innovation, and drive commercial success positions her as a trusted advisor to entrepreneurs and a formidable force in venture capital. Through her work at Polaris Partners, she continues to champion companies that are poised to make a lasting positive impact on human health, solidifying her reputation as a visionary leader in the investment community.
